Antisense Oligonucleotide Composition for TDP-43 Expression Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for TDP-43 proteinopathies, such as amyotrophic lateral sclerosis (ALS), lack an effective therapeutic agent to manage TDP-43 protein accumulation.
Innovation Solution
Development of antisense oligonucleotides targeting TDP-43 mRNA or pre-mRNA, specifically designed to be complementary to certain regions of the TDP-43 sequence, which can modulate its expression and splicing, thereby reducing pathological effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antisense oligonucleotides are designed to target TDP-43 mRNA or pre-mRNA, then TDP-43 expression can be modulated, but the specificity and effectiveness of the treatment remains insufficient
Solution Approach 1:
The patent applies local quality by designing antisense oligonucleotides with specific chemical modifications at particular positions along the sequence. Different regions of the oligonucleotide have different properties (e.g., phosphorothioate bonds at specific locations, modified sugar moieties) to enhance binding specificity to TDP-43 mRNA while reducing off-target effects, thereby improving both targeting precision and treatment reliability.
Solution Approach 2:
The patent employs parameter changes by systematically varying multiple parameters of the antisense oligonucleotide including length (15-30 nucleotides), base sequence composition, chemical modifications (phosphorothioate vs phosphodiester bonds), and sugar moiety modifications. These parameter optimizations enable precise control over binding affinity and specificity to achieve reliable treatment effects.
2Reliability
If existing antisense oligonucleotides are used to adjust TDP-43 expression, then some therapeutic effect is achieved, but the treatment is not effective enough for TDP-43 proteinopathies
Solution Approach 1:
The patent applies composite materials by creating antisense oligonucleotides that combine multiple functional elements: modified sugar moieties (2'-OMe, 2'-O-MOE), phosphorothioate bonds, and specific base sequences. This composite structure provides both the binding affinity needed for therapeutic effect and the specificity required to avoid off-target effects, thereby enhancing overall treatment efficacy.
Solution Approach 2:
The patent uses copying by designing antisense oligonucleotides that are complementary copies of specific regions of TDP-43 mRNA. The oligonucleotide sequence is carefully selected to match critical regions of the mRNA, enabling the antisense molecule to bind specifically and modulate TDP-43 expression effectively.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antisense oligonucleotides effectively target and regulate TDP-43 levels, providing a novel therapeutic approach for TDP-43 proteinopathies.
Implementation Method 1
consisting of 15 to 22 nucleotides complementary to a nucleic acid comprising at least 15 consecutive bases in a target region
Data Source
AI summary
In the present specification, an antisense oligonucleotide or a pharmaceutically acceptable salt thereof, or a hydrate thereof, consisting of 15 to 22 nucleotides complementary to a nucleic acid comprising at least 15 consecutive bases in a target region selected from the group consisting of positions 1 to 102, 159 to 842, 879 to 1822, and 1874 to 4182 from the 5′ end of a base sequence of SEQ ID NO: 1 is provided.